Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Indapamide”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 271 records · Page 15Linked to original sources
PubMed1984

Indapamide versus beta-blocker therapy: a double-blind, crossover study in essential hypertension.

A controlled, double-blind, double-placebo, crossover clinical trial was carried out in 24 mild to moderate hypertensives of either sex to compare the anti-hypertensive and other effects of indapamide (2.5 mg) and pindolol (15 mg). After a 2-week run-in placebo period the patients were randomly assigned to one of the drugs in the study for 6 weeks. After a second 2-week placebo period, the subjects received the alternative drug for an additional 6 weeks. Both drugs produced a significant and similar decrease in arterial blood pressure (averaging 19 mmHg for systolic and 15 mmHg for diastolic blood pressure; p less than 0.05), with minimal differences between the drugs in this respect (p greater than 0.10). Pulse, rate, however, was significantly reduced (from 76 to 67 beats/min; p less than 0.05) only with pindolol. The laboratory data did not change appreciably, and few side-effects were reported. It is concluded that indapamide and pindolol at the dosage levels used are drugs of comparable antihypertensive activity.

Adult↗
PubMed1985

Vasodilator effect of indapamide in dog mesenteric vasculature.

Effects of indapamide, trichlormethiazide and hydralazine on isolated, perfused dog mesenteric vasculature and helical strips of the dog mesenteric artery were compared. It appears that indapamide-induced hypotension is associated with a direct relaxant action on arterial and arteriolar smooth muscle, whereas hydralazine acts exclusively on resistance vessels.

Animals↗
PubMed1983

Once a day indapamide therapy in hypertension. Effects on the heart and peripheral arterial circulation.

Indapamide, a sulphonamide derivative, was prescribed for 8 weeks at low dose (2.5 mg once a day) to 14 hypertensive patients in order to investigate its effects on systolic and diastolic blood pressure (SBP, DBP), cardiac function and peripheral arterial resistance (PAR). During treatment we observed decreases in both SBP and DBP without any change in HR in the supine and standing positions and on exercise. As a result cardiac work was significantly reduced. Slight changes in pre-ejection period (PEP) and left ventricular ejection time (LVET) along with a more significant decrease in rate of rise of left ventricular pressure (DBP to PEP ratio) were observed during treatment. An increase in RBF and a decrease in PAR were also detected in the peripheral circulation. These findings may indicate that indapamide antagonizes the cardiovascular effects of catecholamines.

Adult↗
PubMed1981

Comparison of indapamide with thiazide diuretics in patients with essential hypertension.

The effect of the new diuretic antihypertensive drug, indapamide (2.5 mg a day), was compared with the effect of thiazide diuretics in 24 patients with hypertension (seven of whom were receiving a diuretic alone, six were taking a beta-blocker plus a diuretic, and 11 received other combinations of drugs, including a diuretic in all cases). The randomized crossover study with two six-week phases indicated that indapamide is an effective hypotensive agent with potency similar to that of the thiazide diuretics in lowering the blood pressure and in increasing the excretion of potassium.

Benzothiadiazines↗
PubMed2002

[Tolerability and efficacy of retard form of indapamide in the treatment of hypertension in elderly patients (results of multicenter open non-comparative trial in Russian program ARGUS)].

Open noncomparative multicenter study of tolerability and efficacy of a retard form of indapamide (1.5 mg o.d. for 3 months) in patients older then 55 years was conducted in 14 centers in Russia. Numbers of patients included into was analysis of safety and tolerability were 1277 and 1121, respectively. After 3 months systolic, diastolic and pulse blood pressure (BP) decreased by 20.2, 13.2, 27.5% (supine) and by 19.4, 11.8, 26.9% (standing), respectively. There were no significant changes of heart rate. Effect of treatment was considered positive in 92.4% of patients. Normalization of blood pressure occurred in 51.8% of patients (in 46.2% and 53.4% among men and women, respectively, p=0.0252; in 55.7% and 48% among patients aged <65 and >65 years, respectively). In patients with type II diabetes rates of positive effect and achievement of target BP <130/85 mm Hg were 60.8% and 31.4%, respectively. Hypokaliemia (3.0-3.5 mmol/l) was registered in 43 patients (3.4%), age of 27 of these patients was 65 years. There were no pronounced changes of blood serum levels of creatinine, glucose and uric acid. Significant lowering of atherogeneity cholesterol index occurred in the whole group while both this index and total cholesterol significantly decreased in patients with baseline hypercholesterolemia. Thus in patients older that 55 years monotherapy with retard form of indapamide was demonstrated to be safe and effective antihypertensive intervention.

Aged↗
PubMed1992

[Indapamide in the treatment of hypertension in diabetes].

The authors treated 20 diabetics (14 men and 6 women) in an open clinical trial with indapamide (Arifon, Zorka Co.) for a period of three months, using a morning dose of 2.5 mg. In 10 patients with hypertension stage I in all normalization of the systolic pressure below 18.6 kPa and diastolic pressure below 12 kPa was achieved. Treatment of patients with hypertension stage II was not adequate in 6 patients. In the course of treatment metabolic compensation of diabetes (type 1 or type 2) did not deteriorate. No changes in the blood lipid spectrum and mineral metabolism were recorded. Indapamide is an antihypertensive drug suitable for treatment of mild hypertension in diabetics as monotherapy.

Diabetes Complications↗
PubMed2004

[Effect of fixed low dose combination of perindopril and indapamide on processes of cardiovascular remodeling in previously untreated patients with hypertension].

AIM: To assess changes of blood pressure (BP) and processes of cardiovascular remodeling during treatment of previously untreated patients with hypertension with fixed low dose combination of perindopril and indapamide. MATERIAL: Patients with untreated hypertension (n=30, mean age 46.7+/-1.8 years, 16 men, 14 women) received low-dose perindopril (2 mg) - indapamide (0.625 mg) combination for 6 months. METHODS: Twenty four-hour BP monitoring, measurement of left ventricular (LV) mass index and wall and interventricular septal thickness, carotid artery intima-media thickness, pulse wave velocity and cerebral blood flow velocity. RESULTS: Target BP level was reached in 83.3% of patients. BP monitoring revealed significant lowering of daytime and nocturnal systolic BP (-13.2%, p<0.0001 and -14.5%, p<0.0001, respectively), daytime and nocturnal diastolic BP (- 14.3%, p<0.0001 and -15.3%, p<0.0001, respectively). Significant reduction of LV mass index (-12%, p=0.0002) was also observed. Both LV posterior wall and interventricular septal thicknesses were reduced as well (-5.1%, p<0,01). This was accompanied by decreases of intima-media thickness of right and left carotid arteries (-5,4%, p=0.04 and -5,3%, p=0.01, respectively), reduction of stiffness of elastic arteries (carotid-femoral pulse wave velocity decreased by 8%, p=0.003), and increase of cerebral blood flow velocity. CONCLUSION: The use of perindopril/indapamide combination in hypertensive patients was associated BP lowering and positive effects on remodeling both of the heart and large and medium arteries.

Antihypertensive Agents↗
PubMed2005

[Comparative efficacy of fixed dose combinations of perindopril with indapamide and captopril with hydrochlorothiazide in patients with high risk hypertension].

Clinical effectiveness and tolerability of o.d. use of fixed dose combinations of perindopril (4 mg) with indapamide (1.25 mg) (Noliprel forte) and captopril (50 mg) with hydrochlorothiazide (25 mg) (Capozide) were compared in a randomized study on 40 patients with I-II degree high and very high risk hypertension. Study duration was 6 months, number of patients in each of parallel groups -- 20. Antihypertensive activity, ability to decrease left ventricular hypertrophy, to improve arterial elasticity and T/P parameter of perindopril (4 mg) -- indapamide (1.25 mg) combination was found to be superior to those of captopril (50 mg) -- hydrochlorothiazide (25 mg) combination.

Adrenergic beta-Antagonists↗
PubMed1990

[Severe ventricular arrhythmia secondary to indapamide-induced hypopotassemia].

We report on two patients, treated with indapamide for mild hypertension, who developed life-threatening ventricular arrhythmias. The former showed severe hypokalemia, QT interval prolongation and "torsade de pointes": the latter, who suffered from ischemic heart disease, had slightly decreased serum potassium and ventricular fibrillation. In both cases no other cause accounting for hypokalemia and ventricular arrhythmia was found. Therefore we stress that serum potassium and ECG must be carefully monitored during indapamide therapy, mainly in patients with cardiac disease.

Aged↗
PubMed1990

[Antihypertensive treatment: a combination of delapril, a new ACE-inhibitor, and indapamide].

The controlled study was carried out on 15 patients with essential hypertension not sufficiently controlled after one month of monotherapy with an ACE-inhibitor. To the above therapy was therefore associated a low dosage diuretic (indapamide 2.5 mg/day). The observation period was of 12 weeks. The delapril-indapamide combination was found to be very effective in reducing blood pressure values; no significant metabolic adverse effects were observed.

Adult↗
PubMed1990

[Determination of indapamide in human serum by high performance liquid chromatography].

A HPLC method for determination of indapamide in human serum with Sulfisoxazole as internal standard has been established. This method was carried out ODS column (5 microns). We used a mobile phase of acetonitrile: 0.05 mol/L sodium acetate buffer at pH 3.72 (45:55 V/V) and a flow rate of 1.2 ml/min. The procedure was as follows: Transfer 0.5 ml of patient serum add 10 microliters of the internal standard (0.2 mg/ml) and 9 ml ethyl acetate into 12 ml of glass centrifuge tube. Shake for 10 minutes and centrifuge at 3000 r/min for 10 minutes. Transfer the ethyl acetate phase into another tube and evaporate to dryness at 70 c under a nitrogen steam. Reconstitute the residue with methanol 50 microliters and inject 15 microliters into the chromatograph. This method is simple, rapid, sensitive and has a good linearity. The average recoveries of indapamide and internal standard were 99.5% and 98.5% respectively. The method was linear from 0.04 micrograms/ml to 0.5 micrograms/ml with correlation coefficient of 0.9998. The coefficient of variation was less than 4.6% within a day (n = 8) and less than 4.3% between days (n = 8) respectively.

Chromatography, High Pressure Liquid↗
PubMed1990

[Long-term effects of indapamide in left ventricular hypertrophy in patients with hypertension].

Left ventricular hypertrophy is a major and independent cardiovascular risk factor in hypertension. The effects of a diuretic, indapamide, on the regression of left ventricular hypertrophy were studied in a group of 9 patients with mild hypertension treated in an open therapeutic trial over a 12 month period. At the end of the trial, the left ventricular mass index decreased significantly from 172 +/- 11 to 147 +/- 11 g/m2 (p less than 0.001). Therefore, in contrast to the other diuretics which have been studied, indapamide seems able to induce regression of the left ventricular hypertrophy complicating hypertension.

Adult↗
PubMedDate not supplied

[Hypotensive effectiveness and metabolic effects of indapamide in patients with primary arterial hypertension].

Indapamide--a non-thiazide diuretic agent--was given to 28 patients with mild and moderate hypertension in a daily dose of 2.5 mg for 12 weeks. Statistically significant decrease in both systolic and diastolic blood pressure and complete normalization of the arterial blood pressure were achieved in 82% of the treated patients. Adverse reactions were mild and transient. However, low but statistically significant decrease in blood serum potassium and changes in the carbohydrate metabolism were seen. No significant effect of the-drug on lipid metabolism was found except the low but statistically significant increase in total cholesterol. Indapamide is an efficient and well tolerated hypotensive agent. However, biochemical indices should be checked up during the treatment due to the potential adverse reactions.

Adult↗
PubMed1989

[2 clinical cases of hypopotassemia during treatment with indapamide].

Indapamide, an antihypertensive drug with diuretic and vasodilative effect, causes a reduction in plasmatic potassium concentration that is generally moderate and not such as to cause damages. In the present article two cases are described that showed severe changes due to hypokalaemia resulting from treatment with indapamide.

Aged↗
PubMed1988

Arterial compliance and baroreceptor sensitivity after chronic treatment with indapamide.

Arterial compliance, assessed by the ratio of stroke volume to pulse pressure, and baroreceptor sensitivity (Oxford method), were determined in ten patients with essential hypertension, treated with placebo or indapamide (2.5 mg/day), in a cross-over, single blind study. After three months of therapy, mean arterial pressure was significantly reduced from 127 +/- 10 to 118 +/- 9 mmHg, (P less than 0.001), as was total peripheral vascular resistance (from 3017 +/- 561 to 2457 +/- 614 dyne/sec/cm-5/m2, P less than 0.001). Significant increases occurred in cardiac index (3.47 +/- 0.55 to 4.03 +/- 0.86 l/min/m2, P less than 0.01), baroreceptor sensitivity assessed with phenylephrine (from 11.69 +/- 7.9 to 15.0 +/- 9.1 msec/mmHg, P less than 0.01) or with nitroglycerine (from 4.77 +/- 1.6 to 7.11 +/- 2.7 msec/mmHg, P less than 0.01) and arterial compliance (from 1.27 +/- 0.42 to 1.55 +/- 0.57, P less than 0.01). A significant direct correlation was found between arterial compliance and baroreceptor sensitivity assessed during induced increase and reduction of BP, both during placebo (r = 0.88, P less than 0.001 and r = 0.77, P less than 0.01, respectively) and during active therapy (r = 0.94, P less than 0.001 and r = 0.92, P less than 0.001, respectively). These results support the conclusion that chronic treatment with indapamide enhances arterial compliances and reduces the heart load and blood vessel stress. The same effect could explain the enhancement of baroreceptor sensitivity promoted by the drug.

Adult↗
PubMed1988

Assessment of indapamide in elderly hypertensive patients with special emphasis on well-being.

One hundred forty-nine patients between 56 and 80 years of age with mild to moderate hypertension received indapamide (2.5 mg per day) monotherapy for 12 weeks. In addition to studies of the efficacy and tolerance of indapamide, the study comprised an assessment of well-being, which was carried out objectively by the physician, and subjectively by the patient himself, by means of a list of complaints and a visual analogue scale. The mean blood pressure was lowered from 179/91 mm Hg (supine) before treatment to 149/81 mm Hg at the end of the treatment. The general well-being of the patients, as judged by the physician, showed a markedly positive evolution. The patients themselves indicated that their most frequent symptoms, such as sleep disorders, functional organic disturbances, and sensory and motor fatigue, had improved by 65 to 85 percent, indicating a tendency to better compliance.

Aged↗